Reading MD? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.

QuarterlyIQ Insights · MD

Price

Price, valuation, and the composite score on the same time axis. Scroll over the price chart to zoom.

Price

Daily closes. Earnings/event dots inline.

Close 2026-06-12

Adjusted daily closes (split & dividend). Scroll over the chart to zoom; click a range to reset.

EarningsMaterial event

What it's worth (estimated)

A consensus fair price across 7 valuation methods, at three horizons. Current price $24.30. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.

12-month· primaryinexpensive

$41.52consensus

Range $28.02 – $50.03

vs price: -41% below

Method agreement — · 7 methods

No-growth: today's peer multiple on trailing earnings. The headline read.

3-yearinexpensive

$50.14consensus

Range $27.86 – $61.06

vs price: -52% below

Method agreement — · 5 methods

Embeds projected growth. Leans optimistic by design. Upside context.

5-yearinexpensive

By method

Each method's implied share price per horizon. Provisional rows use a projected (historical-CAGR) growth input rather than analyst or management guidance.

Method	Horizon	Est. price	Multiple	Per-share input	EPS source	Confidence
Peer EV/EBITDA	12M	$31.42	15.5	2.33	TTM	high
Peer P/FCF	12M	$53.35	19.2	2.78	TTM	high
Peer P/E	12M	$41.52	19.4	2.14	TTM	high
Peer P/S	12M	$55.38	2.4	22.63	TTM	high
PEG	12M

P/E history

Monthly trailing P/E with quartile reference lines.

75 monthly points available

Coming next

A “consensus-then vs. actual-now” overlay is on the way — what our valuation estimate said on a past date versus where the price actually landed.

Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.